33 related articles for article (PubMed ID: 38522237)
1. Cannabinoid CB
Zhang HY; Shen H; Gao M; Ma Z; Hempel BJ; Bi GH; Gardner EL; Wu J; Xi ZX
Neuropharmacology; 2021 May; 189():108538. PubMed ID: 33789118
[TBL] [Abstract][Full Text] [Related]
2. Targeting glial cannabinoid CB
Espejo-Porras F; García-Toscano L; Rodríguez-Cueto C; Santos-García I; de Lago E; Fernandez-Ruiz J
Br J Pharmacol; 2019 May; 176(10):1585-1600. PubMed ID: 29574689
[TBL] [Abstract][Full Text] [Related]
3. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.
Santos-García I; Rodríguez-Cueto C; Villegas P; Piscitelli F; Lauritano A; Shen CJ; Di Marzo V; Fernández-Ruiz J; de Lago E
J Neuroinflammation; 2023 May; 20(1):108. PubMed ID: 37149645
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte Colony-Stimulating Factor Enhances Brain Repair Following Traumatic Brain Injury Without Requiring Activation of Cannabinoid Receptors.
Song S; Kong X; Borlongan C; Sava V; Sanchez-Ramos J
Cannabis Cannabinoid Res; 2021; 6(1):48-57. PubMed ID: 33614952
[No Abstract] [Full Text] [Related]
5. Inactivation of the CB
Rodríguez-Cueto C; Gómez-Almería M; García Toscano L; Romero J; Hillard CJ; de Lago E; Fernández-Ruiz J
Brain Pathol; 2021 Nov; 31(6):e12972. PubMed ID: 33983653
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
7. Involvement of CB
Gonzalo-Consuegra C; Santos-García I; García-Toscano L; Martín-Baquero R; Rodríguez-Cueto C; Wittwer MB; Dzygiel P; Grether U; de Lago E; Fernández-Ruiz J
Biomed Pharmacother; 2024 May; 174():116473. PubMed ID: 38522237
[TBL] [Abstract][Full Text] [Related]
8. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.
Espejo-Porras F; Piscitelli F; Verde R; Ramos JA; Di Marzo V; de Lago E; Fernández-Ruiz J
J Neuroimmune Pharmacol; 2015 Jun; 10(2):233-44. PubMed ID: 25819934
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
Svízenská I; Dubový P; Sulcová A
Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
